PCM
BCLI

Penserra Capital Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Penserra Capital Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-332
Closed -$13 – 984
2016
Q1 		$13 Buy
332
+111
+50% +$4.08K ﹤0.01% 492
2015
Q4 		$9K Buy
+221
New +$9.11K ﹤0.01% 530

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
M&T Bank
M&T Bank Buffalo, New York $29.2B AUM 22.81% 1-Year Est. Return

Penserra Capital Management's BCLI Position: Q2 2016 in Review

Penserra Capital Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2016, closing a stake of 332 shares — an estimated $13 sold.

Penserra Capital Management first reported a position in BCLI in Q4 2015 and held it in 2 quarters. The position peaked at $9K in Q4 2015. 22 funds tracked by Wall St. Rank hold BCLI as of Q2 2016.

  • Penserra Capital Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2016 after selling out during the quarter.
  • Penserra Capital Management sold 332 BRAINSTORM CELL THERAPUTC shares in Q2 2016, an estimated $13.
  • Penserra Capital Management first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2015 and held it in 2 quarters.
  • Penserra Capital Management's BRAINSTORM CELL THERAPUTC position peaked at $9K in Q4 2015.
  • 22 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2016.

Based on Penserra Capital Management's 13F filing for Q2 2016, filed 9 Aug 2016.